Literature DB >> 3276451

Ranitidine produces minimal hemodynamic depression in stable intensive care unit patients: a double-blind, prospective study.

S L Goelzer1, C Farin-Rush, D B Coursin.   

Abstract

Ranitidine, a furan H2 receptor antagonist, is increasingly prescribed in the ICU setting. Before the availability of parenteral ranitidine, cimetidine had been the sole H2 blocker used to decrease gastric acidity in this setting. However, cimetidine has recently been shown to transiently, but significantly, reduce mean arterial pressure due to direct vasodilation in a critically ill population. Therefore, this double-blind prospective study was designed to examine the hemodynamic effects of iv ranitidine in an ICU population. Twenty-six critically ill hemodynamically stable patients were studied; all patients were already receiving ranitidine and had an arterial line and a pulmonary artery catheter in place. This study demonstrated that an iv infusion of ranitidine did not produce clinically significant hemodynamic effects in this patient population.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276451     DOI: 10.1097/00003246-198801000-00002

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  3 in total

Review 1.  Side effects of ranitidine.

Authors:  T Vial; C Goubier; A Bergeret; F Cabrera; J C Evreux; J Descotes
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

2.  Diphenhydramine prevents the haemodynamic changes of cimetidine in ICU patients.

Authors:  K Omote; A Namiki; H Iwasaki; Y Ujike
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

Review 3.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.